Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia.,ACS Chemical Neuroscience

当前位置： X-MOL 学术 › ACS Chem. Neurosci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia.
ACS Chemical Neuroscience ( IF 4.1 ) Pub Date : 2018-07-18 , DOI: 10.1021/acschemneuro.8b00205
Santiago G Lago ₁ , Sabine Bahn ₁

Affiliation

There is a paucity of efficacious novel drugs to address high rates of treatment resistance and refractory symptoms in schizophrenia. The identification of novel therapeutic indications for approved drugs-drug repurposing-has the potential to expedite clinical trials and reduce the costly risk of failure which currently limits central nervous system drug discovery efforts. In the present Review we discuss the historical role of drug repurposing in schizophrenia drug discovery and review the main classes of repurposing candidates currently in clinical trials for schizophrenia in terms of their therapeutic rationale, mechanisms of action, and preliminary results from clinical trials. Subsequently we outline the challenges and limitations which face the clinical repurposing pipeline and how novel technologies might serve to address these.

中文翻译：

精神分裂症中药物再利用的临床试验和治疗原理。

缺乏有效的新型药物来解决精神分裂症的高治疗抵抗性和难治性症状。对已批准药物的新治疗指征（重新使用药物）的识别具有加速临床试验和降低失败的代价高昂的风险的潜力，目前这种风险限制了中枢神经系统药物的发现。在本综述中，我们讨论了药物替代疗法在精神分裂症药物发现中的历史作用，并就其在治疗原理，作用机理和临床试验的初步结果等方面，综述了目前在精神分裂症临床试验中主要用途的替代药物候选物。随后，我们概述了临床重用渠道面临的挑战和局限性，以及新技术如何解决这些挑战和局限性。

更新日期：2018-06-26

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11